AlphaStocks
5.9
Consider Buy

LivaNova PLC (LIVN)

As of Sep 20, 2026, LivaNova PLC (LIVN) scores 5.9/10 on AlphaStocks' five-model composite, #57 of 168 Health Care stocks. At $78, LIVN trades 33% above its model fair value of $59.

Health Care / Health Care Equipment

S&P MidCap 400

$78.02

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#57out of 168 in Health Care

Is LivaNova PLC a Good Investment in 2026?

LivaNova PLC (LIVN) scores 5.9 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Lynch model rates LivaNova PLC as Strong. However, the Graham model rates it Caution. LivaNova PLC currently trades 33% above its estimated fair value of $59. LivaNova PLC ranks #57 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-10.8Market Cap4B

Estimated Fair Value

$58.5233% above

Trading above estimated fair value — the market may be pricing in future growth.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Strong

Growth rate vs price (PEG)

Greenblatt

Attractive

Earnings yield 7.6% · ROC 60%

Frequently Asked Questions

Is LivaNova PLC (LIVN) a good investment?
As of Sep 20, 2026, LivaNova PLC (LIVN) scores 5.9/10 on AlphaStocks' five-model composite, #57 of 168 Health Care stocks. At $78, LIVN trades 33% above its model fair value of $59. That is a middle-of-the-pack score with no strong signal either way.
What is LivaNova PLC's Piotroski F-Score?
LivaNova PLC's Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is LIVN overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $59, LIVN appears overvalued. The stock currently trades 33% above its estimated fair value. Trading above estimated fair value — the market may be pricing in future growth.
How does LIVN compare to other Health Care stocks?
LivaNova PLC ranks #57 out of 168 stocks in the Health Care sector, placing it in the top 34% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about LIVN?
AlphaStocks evaluates LIVN using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Caution; Lynch: Strong; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 5.9/10.

Similar Stocks

INSPUFPTBDX

Compare LIVN with

INSP vs LIVNLIVN vs UFPTBDX vs LIVN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer